Cure8 research brief
The study describes a new urine-based fluorescent biosensor that detected inflamed intestinal sites and tracked treatment response earlier and more sensitively than fecal calprotectin in a mouse model of IBD, which could point toward noninvasive diagnostic tools if translated to humans.
Researchers, translational scientists in nanomedicine/biomarkers, and gastroenterology clinicians interested in noninvasive IBD diagnostics
This research reports a synthetic exogenous urinary biomarker (supraNC@PPADT) made of gold nanoclusters inside an ROS-responsive polymer shell. Orally given in mice, the sensor stayed intact in healthy gut tissue but released small gold nanoclusters at inflamed intestinal sites where reactive oxygen species cleaved the shell.
The released nanoclusters were renal-clearable and produced a NIR-II fluorescence signal measurable in urine and by imaging. The authors validated the approach in an IBD mouse model for early diagnosis and to monitor treatment response, and they compare its urine-based detection performance to fecal calprotectin ELISA in their experiments.
This is preclinical, in animals, and does not yet indicate safety, effectiveness, or availability in humans. whoShouldPayAttention: Researchers and clinicians interested in noninvasive IBD diagnostics, biomarker development, and optical imaging; translational scientists working on nanomedicine and urinary assays. moreContext:
This is a preclinical (mouse) experimental report in Biomaterials. Human safety, dosing, and diagnostic performance were not evaluated and will require further studies.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
CMV reactivation can worsen outcomes in active UC and influence treatment choices; clinicians and patients may benefit from additional, easy-to-measure markers that flag higher risk of tissue CMV and prompt targeted...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
